Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Yposkesi
Yposkesi
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
SK pharmteco subsidiary Yposkesi launches AAVelocity, a plug-and-play AAV platform
Designed to shorten turnaround on manufacturing AAVs, this new platform offers CGT developers more flexibility when producing viral vectors for clinical and commercial use
Ingredients
Yposkesi launches lentiviral vector production platform optimised for higher yields
Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, has launched LentiSure
Research & Development
Yposkesi joins BioPhorum CGT consortium
Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a rapidly evolving regulatory environment
Finance
Yposkesi begins construction of second bioproduction site
Backed by majority shareholder SK Pharmteco, Yposkesi is investing $71m in the 5,000 sqm facility. The construction is projected to create approximately 80 jobs by 2023
Manufacturing
Axovant Gene Therapies chooses Yposkesi for viral vector production
The initial focus of the agreement will be on AAV-based gene therapies
Pharmaceutical
Yposkesi appoints Dr Fraser Wright as Senior Advisor
Subscribe now